What is the clinical evidence from this study?

Study design: Other. Population: Doxorubicin-induced cardiotoxicity (n=32). Intervention: Vitamin E and telmisartan vs. Doxorubicin alone. Primary outcome: Serum CK-MB level (IU/L) (p=<0.01).

August 6, 2012BMC Cardiovascular DisordersOpen Access

Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response

Q: What are the key findings of this study?

Pretreatment with vitamin E or telmisartan significantly attenuated doxorubicin-induced cardiotoxicity in rats, reducing serum CK-MB levels and improving left ventricular function.

View Full Paper

Ask AI

Bookmark

Key result

Pretreatment with vitamin E or telmisartan significantly attenuated doxorubicin-induced cardiotoxicity in rats, reducing serum CK-MB levels and improving left ventricular function.

Why the study?

Does pretreatment with vitamin E or telmisartan prevent acute doxorubicin-induced cardiotoxicity in a rat model?

Population

32 male Sprague-Dawley rats

Comparison

Vitamin E followed by doxorubicin OR telmisartan… vs Doxorubicin only and normal saline control

Design

Preclinical, randomly separated into 4 groups

Follow-up

48 hours after completion of treatment (9 days total)

Authors

NHNajah R. HadiUniversity of Kufa NYNasser Ghaly YousifAl-Muthanna University FAFadhil G. Al-AmranUniversity of Kufa

Discussion

Member takes

Overview

Does not support clinical use of vitamin E or telmisartan pretreatment; hypothesis-generating for anthracycline cardioprotection trials.

Structured PICO

Does pretreatment with vitamin E or telmisartan prevent acute doxorubicin-induced cardiotoxicity in a rat model?

Population

32 male Sprague-Dawley rats subjected to doxorubicin-induced cardiotoxicity to evaluate the protective effects of vitamin E and telmisartan.

Intervention

Vitamin E (100 mg/kg orally for 7 days) followed by doxorubicin (20 mg/kg IP single dose) OR telmisartan (1 mg/kg orally for 7 days) followed by doxorubicin (20 mg/kg IP single dose)

Comparator

Doxorubicin only (20 mg/kg IP single dose) and normal saline control

Outcome

Attenuation of doxorubicin-induced cardiotoxicity measured by left ventricular function, inflammatory markers (MCP-1, ICAM-1, macrophage infiltration), and cardiac enzymes (troponin I, CK-MB, LDH)surrogate

Main Result

Absolute Event Rate: 1008.7% vs 4759.1%

p-value: p=<0.01

Pretreatment with vitamin E or telmisartan attenuates acute doxorubicin-induced cardiotoxicity in rats by reducing oxidative stress and inflammatory responses.

Limitations

Animal model may not fully translate to human clinical outcomes
Small sample size
Short follow-up duration
Further investigation needed to know the exact pathway of antioxidant in attenuated Dox induced cardiac injury

Cite This Study

Hadi et al. (2012) studied Doxorubicin-induced cardiotoxicity (n=32). Vitamin E and telmisartan vs. Doxorubicin alone was evaluated on Serum CK-MB level (IU/L) (p=<0.01). Pretreatment with vitamin E or telmisartan significantly attenuated doxorubicin-induced cardiotoxicity in rats, reducing serum CK-MB levels and improving left ventricular function.

synapsesocial.com/papers/6a751b01756843cacbb1e800 https://doi.org/10.1186/1471-2261-12-63

View Full Paper

Ask AI

Bookmark

August 6, 2012BMC Cardiovascular DisordersOpen Access

Vitamin E and telmisartan attenuates doxorubicin induced cardiac injury in rat through down regulation of inflammatory response

View Full Paper

Ask AI

Bookmark

Key result

Pretreatment with vitamin E or telmisartan significantly attenuated doxorubicin-induced cardiotoxicity in rats, reducing serum CK-MB levels and improving left ventricular function.

Why the study?

Does pretreatment with vitamin E or telmisartan prevent acute doxorubicin-induced cardiotoxicity in a rat model?

Population

32 male Sprague-Dawley rats

Comparison

Vitamin E followed by doxorubicin OR telmisartan… vs Doxorubicin only and normal saline control

Design

Preclinical, randomly separated into 4 groups

Follow-up

48 hours after completion of treatment (9 days total)

Authors

NHNajah R. HadiUniversity of Kufa NYNasser Ghaly YousifAl-Muthanna University FAFadhil G. Al-AmranUniversity of Kufa

Discussion

Member takes

Overview

Does not support clinical use of vitamin E or telmisartan pretreatment; hypothesis-generating for anthracycline cardioprotection trials.

Structured PICO

Does pretreatment with vitamin E or telmisartan prevent acute doxorubicin-induced cardiotoxicity in a rat model?

Population

32 male Sprague-Dawley rats subjected to doxorubicin-induced cardiotoxicity to evaluate the protective effects of vitamin E and telmisartan.

Intervention

Vitamin E (100 mg/kg orally for 7 days) followed by doxorubicin (20 mg/kg IP single dose) OR telmisartan (1 mg/kg orally for 7 days) followed by doxorubicin (20 mg/kg IP single dose)

Comparator

Doxorubicin only (20 mg/kg IP single dose) and normal saline control

Outcome

Main Result

Absolute Event Rate: 1008.7% vs 4759.1%

p-value: p=<0.01

Pretreatment with vitamin E or telmisartan attenuates acute doxorubicin-induced cardiotoxicity in rats by reducing oxidative stress and inflammatory responses.

Limitations

Animal model may not fully translate to human clinical outcomes
Small sample size
Short follow-up duration
Further investigation needed to know the exact pathway of antioxidant in attenuated Dox induced cardiac injury

Cite This Study

synapsesocial.com/papers/6a751b01756843cacbb1e800 https://doi.org/10.1186/1471-2261-12-63

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark